Prospective Analysis of Serum HE4 as an Independent Prognostic Factor in Non Small Cell Lung Cancer
ConclusionThere is a negative correlation between Serum HE4 in NSCLC& overall survival, the highest the serum level the shortest the survival. This result can present serum HE4 as a novel prognostic& probably diagnostic marker for NSCLC. (Source: QJM)
Source: QJM - October 1, 2021 Category: Internal Medicine Source Type: research
Effect of Delay in Initiation of Adjuvant Trastuzumab and Dose Interruptions on Overall Treatment Outcome in Breast Cancer Patients, a Retrospective Study
ConclusionWe concluded that delays in the initiation of adjuvant treatment may be particularly harmful in patients with more aggressive tumor types. (Source: QJM)
Source: QJM - October 1, 2021 Category: Internal Medicine Source Type: research
Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before surgery in patients with locally advanced rectal cancer (A phase II study)
ConclusionInduction chemotherapy could be a promising option for better response rates either clinical or pathological for high risk LARC patients with acceptable toxicity profile. (Source: QJM)
Source: QJM - October 1, 2021 Category: Internal Medicine Source Type: research
Prospective non interventional Study Evaluating Prognostic and Predictive value of PDL-1 expression and associated T-cell infiltration in Primary Laryngeal Squamous Cell Carcinoma
Conclusionthere is a positive correlation between tumor infiltration lymphocytes and PDL-1 expression in laryngeal squamous carcinoma and the higher PDL-1 expression in advanced stage laryngeal cancer is associated with better OS. (Source: QJM)
Source: QJM - October 1, 2021 Category: Internal Medicine Source Type: research
Survival outcome and treatment tolerability for postmenopausal females with early stage hormone receptor positive breast cancer treated with different adjuvant hormonal lines (TAM vs. AI vs. switching strategy) for 5 years
ConclusionSimilar disease free survival and overall survival were observed among the three studied groups. Switching tamoxifen to aromatase inhibitors provides better tolerability in terms of endometrial thickness when compared to 5 years of tamoxifen monotherapy. Patients who administer aromatase inhibitor included in the switching strategy experience less osteoporosis and less generalized bone pain compared to upfront aromatase inhibitor to 5 years. There was a significant improvement of disease free survival (DFS) in human epidermal growth factor receptor 2 (HER 2) negative patients receiving any adjuvant hormonal treat...
Source: QJM - October 1, 2021 Category: Internal Medicine Source Type: research
